Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


New weight loss medication may help lower blood pressure in adults with obesity

Written by | 5 Feb 2024

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took… read more.

Zepbound (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks – Eli Lilly

Written by | 16 Dec 2023

Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.

Tirzepatide enhances weight loss with sustained treatment but discontinuation leads to weight regain

Written by | 15 Dec 2023

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine… read more.

CHMP positive for Mounjaro (tirzepatide) for the treatment of obesity – Eli Lilly

Written by | 16 Nov 2023

Eli Lilly’s Mounjaro is recommended for use in Europe for the treatment of obesity. The recommendation comes the same week the drug was approved for obesity treatment in… read more.

FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors – Eli Lilly

Written by | 11 Nov 2023

The FDA approved Eli Lilly and Company’s Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1… read more.

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

Written by | 19 Oct 2023

A phase 3 clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were… read more.

Tirzepatide equally effective for early-onset or later-onset type 2 diabetes

Written by | 10 Oct 2023

Tirzepatide. a once weekly GIP and GLP-1 receptor agonist, treats early-onset type 2 diabetes as effectively as it treats type 2 diabetes diagnosed later in life, researchers reported… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.